Outcome of a Second-Line Protease Inhibitor–Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy
| Autor: | L. Testa, Sara Melzi, Elisabetta Chiesa, Teresa Bini, Fulvio Adorni, B. Castelnuovo, Salvatore Sollima, A d'Arminio Monforte, C. Abeli, Marco Bongiovanni |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Anti-HIV Agents protease inhibitors Pharmacology second-line regimens Pharmacotherapy Indinavir Internal medicine HIV Seropositivity medicine virologic failure Humans Pharmacology (medical) Treatment Failure Adverse effect Saquinavir Acquired Immunodeficiency Syndrome Nelfinavir Ritonavir business.industry intolerance/toxicity HIV Protease Inhibitors Discontinuation CD4 Lymphocyte Count Regimen Treatment Outcome Infectious Diseases Toxicity RNA Viral Drug Therapy Combination Female business medicine.drug Follow-Up Studies |
| Zdroj: | Journal of acquired immune deficiency syndromes (1999) 24 (2000): 115–122. info:cnr-pdr/source/autori:Bini, T; Testa, L; Chiesa, E; Adorni, F; Abeli, C; Castelnuovo, B; Melzi, S; Sollima, S; Bongiovanni, M; Monforte, AD/titolo:Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy/doi:/rivista:Journal of acquired immune deficiency syndromes (1999)/anno:2000/pagina_da:115/pagina_a:122/intervallo_pagine:115–122/volume:24 |
| ISSN: | 1525-4135 |
| DOI: | 10.1097/00042560-200006010-00005 |
| Popis: | The outcome of second-line protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) was investigated in 263 patients who were failed by (n = 148) or intolerant of (n = 115) a first HAART regimen. The endpoints were virologic failure (decline in HIV RNA 34 years versus less than or equal to 34 years: 95% CI, 0.42-0.88), a saquinavir-containing first HAART (HR 0.57 versus indinavir: 95% CI, 0.34-0.93) and change due to intolerance/toxicity (HR 0.58 versus failure: 95% CI, 0.35-0.98). The independent variables predictive of discontinuation due to intolerance/toxicity were the reason for switching (HR 1.79 intolerance versus failure: 95% CI, 1.02-3.16) and the first protease inhibitor (PI) regimen (HR 0.42 ritonavir versus indinavir: 95% CI, 0.22-0.80). Given that patients who are failed by a first regimen are at high risk of having rescue therapy fail as well, second-line regimens including therapies directed by testing of drug resistance patterns of clinical viral isolates are warranted. Patients experiencing toxicity due to a first PI-containing regimen are at risk of toxicity to other PIs and should be addressed to PI-sparing HAART. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|